In the press

eXmoor and Virica receive funding to improve AAV gene therapy manufacturing

Virica Biotech and eXmoor Pharma have announce a new collaboration project funded by a joint UK-Canada government initiative.  This project aims to enhance the manufacturing of adeno-associated vectors (AAVs) crucial for gene therapies, ultimately reducing costs and improving the accessibility of life-saving therapies.  The collaborative project will utilize Virica’s VSEs™, small molecules that have been [...]

eXmoor and Virica receive funding to improve AAV gene therapy manufacturing2024-10-17T09:01:16-04:00

Webinar: Accelerating AAV production: optimizing compound identification and process parameters

Wednesday November 20th,  08:00 PST / 11:00 EST / 16:00 GMT / 17:00 CET Virica Biotech and Culture Biosciences will present innovative solutions to address the high costs associated with gene therapy manufacturing. Real-world case studies will highlight improved productivity, shorter timelines, and more efficient scale-up. Attendees will gain insights into optimizing AAV production using [...]

Webinar: Accelerating AAV production: optimizing compound identification and process parameters2024-10-16T09:16:25-04:00

Virica Biotech and Ginkgo Bioworks Announce Partnership to Accelerate AAV Gene Therapy Manufacturing

Virica Biotech and Ginkgo Bioworks have announced a strategic partnership aimed at improving AAV gene therapy production. Virica will provide a panel of its Viral Sensitizer Enhancers (VSETM) to Ginkgo for high-throughput AAV production screening, while Ginkgo will utilize its advanced screening platform to test VSEs directly in clients' cell lines. This collaboration is expected [...]

Virica Biotech and Ginkgo Bioworks Announce Partnership to Accelerate AAV Gene Therapy Manufacturing2024-10-03T08:32:47-04:00

Invest Ottawa Announces Virica’s IO Accelerator Graduation

Invest Ottawa announces Virica’s graduation from its flagship program following significant growth, increased revenue, team expansion, creating numerous jobs, and securing critical funding. As Virica transitions to the IO ScaleUp program, its aim is to expand services, enter new markets, and continue helping life-saving cell and gene therapies scale. Read Full Article: LINK HERE

Invest Ottawa Announces Virica’s IO Accelerator Graduation2024-07-10T10:38:39-04:00

Virica Launches New Lab Facility with Support from the Government of Canada

  On June 24, 2024, Yasir Naqvi, Parliamentary Secretary to the Minister of Health and Member of Parliament for Ottawa Centre, on behalf of the Honourable Filomena Tassi, Minister responsible for the Federal Economic Development Agency for Southern Ontario (FedDev Ontario), announced a $1.5 million repayable investment to support the expansion of Virica's new facility [...]

Virica Launches New Lab Facility with Support from the Government of Canada2024-06-25T10:19:10-04:00

Virica Awarded NIIMBL Project to Enhance CAR-T Manufacturing

Virica has been selected as a project lead for one of NIIMBL | The National Institute for Innovation in Manufacturing Biopharmaceuticals planned projects, which aim to address key opportunities for innovation in biopharmaceutical manufacturing. NIIMBL is a public-private partnership whose mission is to accelerate biopharmaceutical manufacturing. Virica, with support from NIIMBL members AstraZeneca and Sartorius Stedim Biotech, aims to increase [...]

Virica Awarded NIIMBL Project to Enhance CAR-T Manufacturing2024-04-11T15:06:45-04:00
Go to Top